Copernicus SOCT receives FDA clearance
Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.
Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.
The Copernicus is designed for in vivo imaging and measurement of the retina by using spectral tomography to rapidly create high-resolution images of retinal structures. These detailed three-dimensional images enhance a physician's ability to diagnose and monitor retinal disease and perform pre- and post procedural assessments of patients.
The SOCT was the first commercially available device on the world market.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
